178 related articles for article (PubMed ID: 35859328)
1. PEG-rhG-CSF for prophylaxis of neutropenia after chemotherapy in patients with non-small cell lung cancer: A multicenter, prospective, randomized study.
Sun XS; Wang Z; Ren SH; Zhang HL; Liu LJ; Du HB; Liu XW; Liu JF
Thorac Cancer; 2022 Sep; 13(17):2429-2435. PubMed ID: 35859328
[TBL] [Abstract][Full Text] [Related]
2. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
[TBL] [Abstract][Full Text] [Related]
3. [A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
Xu B; Tian F; Yu J; Song Y; Shi J; Zhang B; Zhang Y; Yuan Z; Wu Q; Zhang Q; Nan K; Sun Q; Li W; Hu J; Bi J; Meng C; Dai H; Jiang H; Yue S; Cao B; Sun Y; Wang S; Tong Z; Shen P; Wu G; Tang L; Deng Y; Jia L; Shen K; Zhuang W; Xie X; Wu Y; Chen L
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):23-7. PubMed ID: 26796802
[TBL] [Abstract][Full Text] [Related]
4. [Application of pegylated recombinant human granulocyte colony-stimulating factor to prevent chemotherapy-induced neutropenia in patients with lymphoma: a prospective, multicenter, open-label clinical trial].
Huang HQ; Bai B; Gao YH; Zou DH; Zou SH; Tan H; Song YP; Li ZY; Jin J; Li W; Su H; Gong YP; Zhong MZ; Shuang YR; Zhu J; Zhang JQ; Cai Z; Teng QL; Sun WJ; Yang Y; Xia ZJ; Chen HL; Hua LM; Bao YY; Wu N
Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):825-830. PubMed ID: 29166732
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of 3 mg pegylated recombinant human granulocyte colony-stimulating factor as support to chemotherapy for lung cancer.
Ji X; Xu L; Pan P; Xu Z; Wang A; Li Y
Thorac Cancer; 2022 Jan; 13(1):117-125. PubMed ID: 34791805
[TBL] [Abstract][Full Text] [Related]
6. Advantages with prophylactic PEG-rhG-CSF versus rhG-CSF in breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy: an open-label, randomized, multicenter phase III study.
Xie J; Cao J; Wang JF; Zhang BH; Zeng XH; Zheng H; Zhang Y; Cai L; Wu YD; Yao Q; Zhao XC; Mao WD; Jiang AM; Chen SS; Yang SE; Wang SS; Wang JH; Pan YY; Ren BY; Chen YJ; Ouyang LZ; Lei KJ; Gao JH; Huang WH; Huang Z; Shou T; He YL; Cheng J; Sun Y; Li WM; Cui SD; Wang X; Rao ZG; Ma H; Liu W; Wu XY; Shen WX; Cao FL; Xiao ZM; Wu B; Tian SY; Meng D; Shen P; Wang BY; Wang Z; Zhang J; Wang L; Hu XC
Breast Cancer Res Treat; 2018 Apr; 168(2):389-399. PubMed ID: 29230663
[TBL] [Abstract][Full Text] [Related]
7. A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF).
Huang X; Li S; Shi W; Wang Y; Wan X; He J; Xu Y; Zhang W; Shi X; Chen R; Xu L; Zha X; Wang J
Br J Clin Pharmacol; 2023 Jan; 89(1):372-379. PubMed ID: 36001055
[TBL] [Abstract][Full Text] [Related]
8. A multicenter phase II trial of primary prophylactic PEG-rhG-CSF in pediatric patients with solid tumors and non-Hodgkin lymphoma after chemotherapy: An interim analysis.
Huang J; Lu S; Wang J; Jiang L; Luo X; He X; Wu Y; Wang Y; Zhu X; Chen J; Tang Y; Chen K; Tian X; Shi B; Guo L; Zhu J; Sun F; Zhen Z; Zhang Y
Cancer Med; 2023 Jul; 12(13):14130-14137. PubMed ID: 37183837
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
Zhou C; Huang Y; Wang D; An C; Zhou F; Li Y; Chen G; Wu C; He J; Wu G; Song X; Gao J; Liu W; Li B; Shi J; Huang C; Yu J; Feng J; Yue H; Shi M; Xia J
Clin Lung Cancer; 2016 Mar; 17(2):119-27. PubMed ID: 26781346
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
Jiang Y; Zhang J; Zhong J; Liao H; Zhang J; Liu Y; Liang Y; Li H
BMC Cancer; 2023 Jul; 23(1):702. PubMed ID: 37495949
[TBL] [Abstract][Full Text] [Related]
11. A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer.
Zou D; Guo M; Zhou Q
BMC Cancer; 2021 Jun; 21(1):661. PubMed ID: 34078317
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
[TBL] [Abstract][Full Text] [Related]
13. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor].
Shi YK; Liu P; Yang S; Han XH; He XH; Ai B; Qin Y; Li B; Huang DZ; Zhang CG; Sun Y
Ai Zheng; 2006 Apr; 25(4):495-500. PubMed ID: 16613688
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled clinical trial of polyethylene glycol recombinant human granulocyte colony-stimulating factor in the treatment of neutropenia after chemotherapy for breast cancer.
Huang W; Liu J; Zeng Y; Wu F; Li N; Chen K; Hong Y; Wang L; Zhen H; Lin L
Cancer Chemother Pharmacol; 2018 Oct; 82(4):607-613. PubMed ID: 30043207
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte-colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study.
Liu C; Hao Y; Wang L; Meng F; Wen F; Zhong D
Thorac Cancer; 2021 Apr; 12(8):1154-1161. PubMed ID: 33590721
[TBL] [Abstract][Full Text] [Related]
16. [The role of prophylactic use of pegylated recombinant human granulocyte colony-stimulating factor(PEG-rhG-CSF) in breast cancer receiving adjuvant chemotherapy].
Zhang JY; Liu YX; Wang H; Mi L; Song GH; Jiang HF; Yan Y; Shao B; Kong WY; Zhang RY; Ran R; Liu XR; Wang J; Lin YT; Li HP
Zhonghua Yi Xue Za Zhi; 2018 Sep; 98(34):2718-2721. PubMed ID: 30220167
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of PEG-rhG-CSF in preventing chemoradiotherapy-induced neutropenia in patients with locally advanced cervical cancer.
Li W; Dong M; Huang S; Shi L; Yang H; Zhang Y; Gong J; Shi M; Wei L; Zhao L
Biomol Biomed; 2023 Mar; 23(2):310-316. PubMed ID: 36300280
[TBL] [Abstract][Full Text] [Related]
18. [A multicenter, randomized, controlled, phase Ⅳ clinical study of PEG-rhG-CSF for preventing chemotherapy induced neutropenia in patients with breast cancer].
Jiang ZF; Xu FR; Fan J; Li BJ; Gao JN; Hu JW; Wang XJ; Zhang YQ; Wang JH; Li F; Liu Q; Liu YH; Wang S; Wang YS; Ouyang QC; Hu B; Sun GP; Zhang Y; Zang AM; Fan PZ; Wu CP; Liu J; Zhang HW; Wang W; Hu XC; Tang LL; Zhang J; Bao YY; Geng CZ; Sun Q; Zhang F; Yin YM; Jiang HC; An YH
Zhonghua Yi Xue Za Zhi; 2018 Apr; 98(16):1231-1235. PubMed ID: 29747310
[No Abstract] [Full Text] [Related]
19. Pegylated recombinant human granulocyte colony-stimulating factor regulates the immune status of patients with small cell lung cancer.
Sun J; Bai H; Wang Z; Duan J; Li J; Guo R; Wang J
Thorac Cancer; 2020 Mar; 11(3):713-722. PubMed ID: 32020764
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial.
Wang C; Zhu S; Miao C; Wang Y; Chen J; Yuan S; Hu X
BMC Cancer; 2022 May; 22(1):542. PubMed ID: 35562713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
